[go: up one dir, main page]

EP0250991B1 - Procédé pour déterminer la teneur en fructoseamine de sérum et mélange de réactifs approprié - Google Patents

Procédé pour déterminer la teneur en fructoseamine de sérum et mélange de réactifs approprié Download PDF

Info

Publication number
EP0250991B1
EP0250991B1 EP87108517A EP87108517A EP0250991B1 EP 0250991 B1 EP0250991 B1 EP 0250991B1 EP 87108517 A EP87108517 A EP 87108517A EP 87108517 A EP87108517 A EP 87108517A EP 0250991 B1 EP0250991 B1 EP 0250991B1
Authority
EP
European Patent Office
Prior art keywords
reagent
agent
blood
enzymatic
fructosamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP87108517A
Other languages
German (de)
English (en)
Other versions
EP0250991A3 (en
EP0250991A2 (fr
Inventor
Joachim Dr.Rer.Nat. Siedel
Joachim Dr.Rer.Nat. Ziegenhorn
Lieselotte Schellong
Bernd Dr.Med. Vogt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Roche Diagnostics GmbH
Priority to AT87108517T priority Critical patent/ATE85131T1/de
Publication of EP0250991A2 publication Critical patent/EP0250991A2/fr
Publication of EP0250991A3 publication Critical patent/EP0250991A3/de
Application granted granted Critical
Publication of EP0250991B1 publication Critical patent/EP0250991B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/02—Food
    • G01N33/08—Eggs, e.g. by candling
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/904—Oxidation - reduction indicators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials

Definitions

  • the present invention relates to a method for the specific determination of the serum fructosamine content in blood or blood-derived samples while avoiding the protein matrix effect.
  • Serum fructosamine content means the total content of non-enzymatically glycosylated serum proteins. These arise because serum glucose forms Schiff bases with free protein amino residues via their carbonyl group. These are then converted into fructosamines with a stable ketoamine bond by Amadori rearrangement.
  • the reaction mechanism was e.g. B. by E. Schleicher and OH Wieland in J. Clin. Chem. Clin. Biochem. (1981) 19 , 81-87.
  • fructosamine formation is proportional to the blood glucose level. As is known, this can be subject to strong fluctuations in connection with pronounced pathological phenomena in diabetics, especially in the case of insufficient dietary and medicinal metabolic adjustment.
  • the blood glucose determination only gives the doctor information about the metabolic status at the time of blood collection.
  • a long-term control of the metabolic status of the past 120 days is possible with the determination of glycosylated hemoglobin (HbA1).
  • the measurement of the serum fructosamine is now suitable because of its half-life, to retrospectively determine the metabolic management of diabetics through lifestyle and therapeutic measures over a medium-term period of approx. 3 weeks.
  • blood glucose and glycosylated hemoglobin (HbA1) the diagnostic arsenal for the monitoring of diabetics could be extended by a valuable medium-term parameter with a reliable, specific and practicable method for the determination of serum fructosamine.
  • EP-A-0215 170 describes an end point test for fructosamine in which a number of possible measures are proposed for eliminating disturbing nonspecifically reducing sample components. In addition to the preferred measure of sample incubation with a NaOH solution at pH 10 for at least 30 minutes, a number of less preferred measures are also mentioned, such as. B. sample incubation at higher temperature, desalting of the sample solution via dialysis or gel permeation chromatography or addition of enzymatic or non-enzymatic oxidizing agents. Serum fructosamine determinations have also suffered from disorders which are based on the total protein content which varies from sample to sample. They lead to fluctuations in measured values and thereby reduce the sensitivity of the determination method. These disorders are known as matrix effects.
  • fructosamine in hyperlipemic sera.
  • a sample / reagent volume ratio of 0.1 is required.
  • the resulting turbidity of the test batch has a negative effect on the photometric measurement. The determination of fructosamine is made considerably more difficult or even prevented.
  • GB-A-2084 726 generally describes a way of removing turbidity in biological samples with a nonionic detergent and cholesterol esterase or lipase.
  • a reference to a fructosamine test or to the elimination of a protein matrix effect which interferes with this is not contained in this application.
  • the object of the present invention was to provide such a method.
  • the method according to the invention for the specific determination of the serum fructosamine content in blood or blood-derived samples by reaction with a redox color reagent and measurement of the color change caused thereby Avoiding the protein matrix effect is characterized in that before the color reaction the sample is treated with one or more enzymatic or / and non-enzymatic oxidizing agents, lipase and one or more detergents at a pH between 6 and 9, then a pH between 10 and 12 set and the color reagent is added.
  • Ascorbate oxidase, bilirubin oxidase or / and uricase are advantageously used as enzymatic oxidizing agents and hypochlorite or a hypochlorite-providing compound is used as non-enzymatic oxidizing agent.
  • N-chloro-p-toluenesulfamide (chloramine T) is particularly suitable as the hypochlorite-providing compound. The compound slowly releases hypochlorous acid on contact with water. The latter is an effective oxidizing agent in acid to neutral, but not in alkaline. It has proven particularly advantageous if additional peroxidase and / or catalase are added.
  • Catalase if any, is used primarily to remove excess hydrogen peroxide.
  • a suitable detergent advantageously a cationic detergent, for example oxyethylalkylammonium phosphate (eg Dehyquart R SP from Henkel)
  • a cationic detergent for example oxyethylalkylammonium phosphate (eg Dehyquart R SP from Henkel)
  • the oxidative effect can surprisingly be increased.
  • a mixture of enzymatic and / or non-enzymatic oxidizing agents is particularly effective, if it contains chloramine T and at the same time a cationic detergent, e.g. oxyethylalkylammonium phosphate (e.g. Dehyquart R SP).
  • the concentration of cationic detergent ranges from 0.5 to 4% by volume. 1 to 2% by volume has proven to be the preferred concentration range for Dehyquart R SP.
  • lipase if appropriate, to the oxidizing agent (s), optionally together with one or more detergents and / or salts of strong acids.
  • oxidizing agent s
  • detergents and / or salts of strong acids With the help of such a mixture it is possible to eliminate substances that cause turbidity to such an extent that the subsequent color measurement is no longer impaired.
  • a solution which contains the enzymatic or / and non-enzymatic oxidizing agent, lipase and one or more detergents and optionally salts of strong acids in a suitable non-reducing buffer All buffer substances which do not themselves have a reducing effect and whose buffering effect is at approximately neutral pH are suitable for the preparation of this solution.
  • the buffer concentration is preferably 10-100 mmol / l, very particularly preferably 20-70 mmol / l.
  • Aqueous potassium phosphate buffer has proven to be particularly advantageous.
  • the concentration of the added enzymes depends on the concentration of the interfering compounds to be removed. These enzyme concentrations are usually between 0.01 and 10,000 U / ml. Preferred concentration ranges are, for example Uricase 1 - 15 U / ml Bilirubin oxidase 0.05 - 5 U / ml Ascorbate oxidase 2 - 20 U / ml Lipase 0.5 - 5 U / ml Peroxidase 0.5 - 5 U / ml Catalase 100-10,000 U / ml
  • concentration ranges for these enzymes are for Uricase 2 - 10 U / ml Bilirubin oxidase 0.1 - 1 U / ml Ascorbate oxidase 5 - 15 U / ml Lipase 1 - 3 U / ml Peroxidase 1 - 3 U / ml Catalase 500 - 2000 U / ml.
  • the concentration of the added hypochlorite or the hypochlorite-providing compounds also depends on the concentration of the interfering compounds to be removed.
  • Hypochlorite and hypochlorite-providing compounds are usually used in concentrations of 50 to 600 ⁇ mol / l, preferably 150 to 300 ⁇ mol / l.
  • detergents can also be anionic or nonionic detergents.
  • Alkali or alkaline earth metal salts of bile acids and their conjugates are preferred as anionic detergents.
  • Advantageous concentrations of anionic detergents are between 2 and 10 mmol / l.
  • Sodium cholate in concentrations of 4 to 6 mmol / l has proven to be particularly favorable.
  • a wide range of detergents is available as a nonionic detergent.
  • Linear or branched chain alkyl or alkylaryl alcohol polyglycol ethers with 8 to 20 carbon atoms in the alcohol part and 4 to 15 glycol units per molecule have proven to be particularly suitable.
  • a particularly advantageous activating effect is exerted by linear and branched-chain alkyl alcohol polyglycol ethers having 8 to 12 carbon atoms in the alcohol part and 4 to 8 glycol units per molecule.
  • nonionic detergents are suitable which can be uniform with regard to the structure of the alcohol part or a mixture of several polyglycol ethers which differ with respect to the structure of the alcohol part.
  • the concentration of nonionic detergent which is used according to the invention to eliminate the protein matrix effect ranges from 0.05 to 15% by weight. 0.1 to 1% has proven to be the preferred concentration range for Oxetal R ID 104, and 0.2 to 0.5% has proven particularly advantageous.
  • Product RT 240 R can be used in concentrations of 1 to 10%, particularly advantageously 2 to 5%.
  • the haze-eliminating effect can be enhanced by higher ionic strengths in the reaction solution.
  • Additions of salts of strong acids, which remain in solution even in the alkaline pH range, have proven to be favorable for this.
  • Alkali or alkaline earth metal salts of hydrochloric or sulfuric acid are preferred.
  • Potassium or sodium chloride is particularly preferably used.
  • the concentration of the salts of strong acids ranges from 20 to 100 mmol / l. Salts in a concentration of 40 to 60 mmol / l are particularly preferably added.
  • Non-specific reducing and turbidity-causing sample components are removed at temperatures between 25 and 40 ° C., preferably at 37 ° C. over a period of 1 to 15 minutes, preferably 2 to 6 minutes.
  • the time period to be selected for the incubation depends on the amount of nonspecifically reducing and turbidity-causing sample components and the amount of enzymatic and / or non-enzymatic oxidizing agents, lipase and detergents used to remove them.
  • the incubation for the removal of nonspecifically reducing and turbidity-causing sample components is carried out at an approximately neutral pH value due to the pH optimum of the enzymes used, but the color reaction between the color reagent and fructosamine takes place at a pH value between 10 and 12, it is necessary to buffer after incubation.
  • the pH value is increased by means of a buffer, the pH value of which is slightly above the pH value to be set.
  • a buffer with a pH between pH 10.5 and 12.5, particularly preferably between pH 10.7 and 12.2, is particularly expedient.
  • a carbonate buffer is advantageously used for this purpose, the concentration of which is 150 to 300 mmol / l, particularly preferably 180 to 220 mmol / l.
  • the reducing effect of the fructosamine can be made visible by adding a color reagent in the alkaline range.
  • a tetrazolium salt is preferably used for this, the formazan dye formation of which can be monitored visually or photometrically.
  • Preferred tetrazolium salts are those which are described in "Methods of Enzymatic Analysis” (HU Bergmeyer, ed., 3rd edition, Verlag Chemie Weinheim 1983, Volume I, page 200). Nitrotetrazolium blue (NBT) or 3- (4 ', 5'-dimethylthiazolyl-2 -) - 2,4-diphenyl-tetrazolium bromide (MTT) are particularly suitable.
  • the color reagent can be added to the test mixture both after the buffering and simultaneously with the buffer. For this purpose, it has proven to be advantageous to dissolve the color reagent in the buffer required for the buffering. Concentrations of 0.2 to 2 mmol / l have proven to be favorable for tetrazolium salts, and 0.4 to 1.5 mmol / l have been found to be particularly favorable.
  • the pH of the test mixture has a pH between 10 and 12, preferably 10.3 to 10.6, in the presence of the color reagent.
  • the buffered solution is incubated at temperatures between 25 and 40 ° C, preferably at 37 ° C.
  • the color change based on the reduction of the color reagent is monitored photometrically in a defined time interval, preferably 1 to 15 minutes after buffering.
  • a first measurement is made 1 to 10 minutes after the buffering and a last measurement 2 to 15 minutes after the buffering.
  • two or more measurements can be carried out.
  • the time intervals between two measurements are variable. They can be selected depending on the equipment, and can range from a few seconds to a few minutes.
  • Suitable standard solutions are known.
  • the method described by Johnson et al. in Clin. Chim. Acta (1982) 127 , 87-95 standard can be used, which is based on a matrix of human albumin with defined additions of a synthetic fructosamine.
  • 1-Deoxy-1-morpholino-fructose (DMF) is used as the synthetic fructosamine.
  • the determined serum fructosamine concentration in the sample is given in DMF units when using this standard.
  • the method according to the invention also allows the sample / reagent volume ratio of 0.1, which is based on the method by Johnson et al. It is customary to reduce significantly without the measurement signal with a defined amount of a fructosamine analog used as a sample being significant compared to the same measurement interval and incubation at the same temperature by Johnson et al. described method becomes smaller. Is used as fructosamine analog z. B. DMF used, the sample / reagent volume ratio can be reduced to 0.02 in this case without reducing the sensitivity of the measurement.
  • the method according to the invention for the determination of fructosamine in blood or blood-derived samples, while avoiding the protein matrix effects with the help of one or more enzymatic and / or non-enzymatic oxidizing agents, lipase and one or more detergents can not only be carried out in solution. It can also be easily transferred to determination methods using dry chemical test carriers.
  • the one or more enzymatic and / or non-enzymatic oxidizing agents, lipase and one or more detergents, optionally salts, possibly with other auxiliaries, are applied to solid carriers in a manner known per se. Suitable solid supports and methods for applying these substances or mixtures of substances to such supports are known to the person skilled in the art. All possible absorbent materials, such as paper, nonwovens, etc., are suitable as carrier materials.
  • the substances to be applied can be taken up in one or more impregnation solutions.
  • the carriers are impregnated or sprayed with these solutions. It is then dried.
  • oxidizing agent s
  • lipase e.g., EDTA
  • optionally salts e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
  • the sample to be measured is first brought into contact with a carrier which contains the oxidizing agent (s), lipase and one or more detergents and optionally salts. After sufficient contact, the pretreated sample is transferred to a layer which contains the other reaction components required for the color reaction. The color change caused is photometric, for. B. measured by reflectometry. With regard to the time intervals for the pre-reaction and for the color reaction, the statements made above apply.
  • Another object of the invention is an agent for the specific determination of the serum fructosamine content in blood or blood-derived samples while avoiding the protein matrix effect, which is characterized in that it consists of a reagent containing enzymatic and / or non-enzymatic oxidizing agents, lipase and detergents, a re-buffering reagent a buffer with a pH in the range of 10.5 - 12.5 and a redox color reagent for the detection of fructosamine.
  • This reagent mixture contains all the components necessary for carrying out the method according to the invention.
  • the agent additionally contains salts of strong acids and, if appropriate, customary additives in a buffer with an approximately neutral pH.
  • Enzymatic oxidizing agents are in particular ascorbate oxidase, bilirubin oxidase and uricase, and non-enzymatic oxidizing agents are to be understood in particular as hypochlorite and hypochlorite-providing compounds.
  • the detergents contained in the agent according to the invention can be anionic or nonionic. While the preferred anionic detergents are alkali or alkaline earth salts of bile acids and their conjugates, a wide range of detergents is available for nonionic detergents. Linear or branched-chain alkyl or alkylaryl alcohol polyglycol ethers with 8-20 C atoms in the alcohol part and 4 to 15 glycol units per molecule have proven to be particularly suitable. However, the detergents added can additionally also be cationic detergents, such as, for example, oxyethylalkylammonium phosphate (for example Dehyquart R SP from Henkel).
  • oxyethylalkylammonium phosphate for example Dehyquart R SP from Henkel
  • a mixture of enzymatic and / or non-enzymatic oxidizing agents is particularly effective if it contains chloramine T and at the same time a cationic detergent, for example Dehyquart R SP.
  • Alkali or alkaline earth metal salts of hydrochloric or sulfuric acid have been found to be suitable as salts of strong acids for the reagent according to the invention.
  • Potassium or sodium chloride are particularly preferred.
  • the buffer required to achieve an approximately neutral pH of the reagent according to the invention has a pH in the range from pH 6-9, preferably pH 7-8.5, very particularly preferably pH 7.5-8.0.
  • the buffer concentration is preferably 10-100 mmol / l, very particularly preferably 20-70 mmol / l.
  • Aqueous potassium phosphate buffer has proven to be particularly advantageous.
  • the change in extinction / minute is linearly proportional to the DMF concentration in the sample up to at least 10 mmol / l.
  • a human serum with bilirubin was gradually increased up to a concentration of 12 mg / dl and the test was carried out as described in Example 1.
  • the measurement signal generated by DMF in the sample is tested in the Johnson et al. very greatly reduced with increasing protein concentrations, while in the test according to the method according to the invention it is practically unaffected by the amount of protein up to at least 100 g RSA / l.
  • the concentrations of fructosamine were determined analogously to Example 1 as DMF units and plotted in mmol / l on the ordinate in FIG. 5a. These results were plotted against the measured values obtained by measuring furosin with the HPLC reference method (J. Clin. Chem. Clin. Biochem. 19 (1981), pp. 81-87). Relative peak area units were used in each case as HPLC measured values.
  • Fig. 5c gives the measurement results for an analog fructosamine determination, in which an additional 250 ⁇ M chloramine T is contained in reagent I.
  • Fig. 5d finally gives the measurement results for an analog fructosamine determination, with both 1.2% Dehyquart R SP and 250 ⁇ M chloramine T also being contained in reagent I.
  • the diagrams 5a-d show that the combination of chloramine T and Dehyquart R SP in particular significantly reduces the intercept.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Claims (14)

  1. Procédé pour la détermination spécifique de la teneur en fructosamine sérique dans le sang ou dans des échantillons dérivés du sang, par réaction avec un réactif colorant redox et mesure du changement de couleur ainsi obtenu, en évitant les effets de la matrice protéique, caractérisé en ce qu'avant la réaction colorimétrique, on traite l'échantillon avec un ou plusieurs agents oxydants enzymatiques ou non enzymatiques, des lipases et un ou plusieurs détergents, à un pH compris entre 6 et 9, puis on ajuste le pH à une valeur comprise entre 10 et 12, et l'on introduit le réactif colorant.
  2. Procédé selon la revendication 1, caractérisé en ce que, comme agent oxydant enzymatique, on utilise l'ascorbate-oxydase, la bilirubine-oxydase et/ou l'uricase.
  3. Procédé selon la revendication 1, caractérisé en ce que, comme agent oxydant non enzymatique, on utilise l'hypochlorite ou un composé libérant de l'hypochlorite.
  4. Procédé selon l'une quelconque des revendications 1 à 3, caractérisé en ce que, comme agent oxydant non enzymatique, on utilise le N-chloro-p-toluènesulfamide et comme détergent, le phosphate d'oxyéthylammonium.
  5. Procédé selon l'une quelconque des revendications 1 à 4, caractérisé en ce que l'on ajoute en plus de la peroxydase et/ou de la catalase.
  6. Procédé selon l'une quelconque des revendications 1 à 5, caractérisé en ce que l'on ajoute en plus des sels alcalins ou alcalino-terreux de l'acide chlorhydrique ou de l'acide sulfurique.
  7. Procédé selon la revendication 1, caractérisé en ce que, pour ajuster la valeur du pH entre 10 et 12, l'on ajoute un tampon qui présente un pH dans la gamme de 10,5 à 12,5.
  8. Procédé selon la revendication 7, caractérisé en ce que, en même temps que le tampon, qui présente un pH dans la gamme de 10,5 à 12,5, on ajoute le réactif colorant.
  9. Agent pour la détermination spécifique de la teneur en fructosamine sérique dans le sang ou dans des échantillons dérivés du sang, en évitant les effets de la matrice, caractérisé en ce qu'il est constitué par un réactif contenant des agents oxydants enzymatiques et/ou non enzymatiques, des lipases et des détergents, un réactif tampon contenant un tampon qui présente un pH compris entre 10,5 et 12,5, et un réactif colorant redox, pour la détermination de la fructosamine.
  10. Agent selon la revendication 9, caractérisé en ce qu'il contient, comme agent oxydant enzymatique, l'ascorbate-oxydase, la bilirubine-oxydase et/ou l'uricase.
  11. Agent selon la revendication 9, caractérisé en ce qu'il contient, comme agent oxydant non enzymatique, l'hypochlorite ou un composé libérant de l'hypochlorite.
  12. Agent selon l'une quelconque des revendications 9-11, caractérisé en ce que, comme agent oxydant non enzymatique, il contient le N-chloro-p-toluènesulfamide et comme détergent cationique, le phosphate d'oxyéthylammonium.
  13. Agent selon l'une quelconque des revendications 9-12, caractérisé en ce qu'il contient en outre de la peroxydase et/ou de la catalase.
  14. Agent selon l'une quelconque des revendications 9-13, caractérisé en ce qu'il contient en outre des sels alcalins ou alcalino-terreux de l'acide chlorhydrique ou de l'acide sulfurique.
EP87108517A 1986-06-21 1987-06-12 Procédé pour déterminer la teneur en fructoseamine de sérum et mélange de réactifs approprié Expired - Lifetime EP0250991B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87108517T ATE85131T1 (de) 1986-06-21 1987-06-12 Verfahren zur spezifischen bestimmung des serumfructosamingehalts sowie hierfuer geeignetes reagenzgemisch.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863620817 DE3620817A1 (de) 1986-06-21 1986-06-21 Verfahren zur spezifischen bestimmung des serumfructosamingehalts sowie hierfuer geeignetes reagenzgemisch
DE3620817 1986-06-21

Publications (3)

Publication Number Publication Date
EP0250991A2 EP0250991A2 (fr) 1988-01-07
EP0250991A3 EP0250991A3 (en) 1988-11-17
EP0250991B1 true EP0250991B1 (fr) 1993-01-27

Family

ID=6303412

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87108517A Expired - Lifetime EP0250991B1 (fr) 1986-06-21 1987-06-12 Procédé pour déterminer la teneur en fructoseamine de sérum et mélange de réactifs approprié

Country Status (11)

Country Link
US (2) US5156947A (fr)
EP (1) EP0250991B1 (fr)
JP (1) JPH0640836B2 (fr)
KR (1) KR880000797A (fr)
AT (1) ATE85131T1 (fr)
AU (1) AU583737B2 (fr)
CA (1) CA1298179C (fr)
DE (2) DE3620817A1 (fr)
DK (1) DK314987A (fr)
ES (1) ES2053468T3 (fr)
YU (1) YU46053B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
DE3732688A1 (de) * 1987-09-29 1989-04-13 Boehringer Mannheim Gmbh Verfahren zur spezifischen bestimmung des serumfructosamingehalts sowie hierfuer geeignetes reagenzgemisch
DE68925387T2 (de) * 1988-06-22 1996-08-14 Hygeia Sciences Ltd Verfahren zur Behandlung von Immunotest-Proben, die Schleim enthalten
DE3822749A1 (de) * 1988-07-05 1990-01-11 Boehringer Mannheim Gmbh Fructosamin-calibrator
DE3824562A1 (de) * 1988-07-19 1990-02-01 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JP2694004B2 (ja) * 1989-03-24 1997-12-24 三光純薬株式会社 血清又は血漿中のフルクトサミンの測定法
JP2775847B2 (ja) * 1989-05-12 1998-07-16 東洋紡績株式会社 フルクトサミン測定用試薬
US4956301A (en) * 1989-11-02 1990-09-11 Miles Inc. Test device and method of assaying for fructosamines
JP2796150B2 (ja) * 1989-12-20 1998-09-10 株式会社ヤトロン フルクトサミンの測定方法
US5565170A (en) * 1990-08-30 1996-10-15 Kyoto Daiichi Kagaku Co., Ltd. Multilayer analytical element for assaying fructosamine
JP2950592B2 (ja) * 1990-08-30 1999-09-20 株式会社京都第一科学 フルクトサミン測定用多層分析用具
US5312760A (en) * 1992-06-08 1994-05-17 Modrovich, Ivan Endre Fructosamine reagent and calibrator system
CA2127679A1 (fr) * 1993-07-27 1995-01-28 Ewald Vorberg Ensemble de reactifs pour la determination de la teneur en fructosamine
US5484753A (en) * 1994-03-08 1996-01-16 Matsushita Electric Industrial Co., Ltd. Dielectric ceramic compositions
JPH086191A (ja) 1994-06-17 1996-01-12 Konica Corp ハロゲン化銀粒子、該粒子を含有するハロゲン化銀乳剤及び該乳剤を含有するハロゲン化銀写真感光材料
ES2136418T3 (es) * 1995-05-05 1999-11-16 Genzyme Ltd Determinacion de proteinas glicosiladas.
US5916746A (en) * 1996-05-09 1999-06-29 Kirkegaard & Perry Laboratories, Inc. Formazan-based immunoassay
EP1320753A2 (fr) * 2000-09-25 2003-06-25 Abbott Laboratories Methodes et trousses permettant de reduire les interferences dans des echantillons d'analyse de plasma ou de serum dans le cadre d'essais de liaison
CN100430488C (zh) * 2001-01-31 2008-11-05 旭化成制药株式会社 测定糖化蛋白质的组合物
US7390674B2 (en) * 2005-03-14 2008-06-24 Kimberly-Clark Worldwide, Inc. Lateral flow devices using reactive chemistry
JP5465008B2 (ja) * 2007-10-30 2014-04-09 パナソニック株式会社 ヘモグロビン及びヘモグロビン誘導体の測定方法、測定キット
CN112326639B (zh) * 2020-11-25 2024-01-05 迈克生物股份有限公司 检测果糖胺的试剂盒和方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2625834B2 (de) * 1976-06-09 1978-10-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Bestimmung von Substraten oder Enzymaktivitäten
US4166763A (en) * 1976-12-10 1979-09-04 Eastman Kodak Company Analysis of lactic acid or lactate using lactate oxidase
DE2816229C2 (de) * 1978-04-14 1983-11-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Beseitigung von Trübungen
DE2907628C2 (de) * 1979-02-27 1981-02-05 C.A. Greiner Und Soehne Gmbh & Co Kg, 7440 Nuertingen Proberöhrchen für die Untersuchung von Proben im klinischen Bereich, insbesondere von Urinproben
DE2910737C2 (de) * 1979-03-19 1984-01-19 Ewald 6701 Dannstadt-Schauernheim Blees Verfahren zur Ausschaltung störender Begleitreaktionen bei enzymatischen Analysenverfahren
DE2914487A1 (de) * 1979-04-10 1980-10-30 Boehringer Mannheim Gmbh Verfahren und mittel zur entfernung von ascorbinsaeure aus waessrigen fluessigkeiten
DE2925534A1 (de) * 1979-06-25 1981-01-22 Boehringer Mannheim Gmbh Verfahren und reagens zur bestimmung von fructose
JPS56151498A (en) * 1980-04-26 1981-11-24 Wako Pure Chem Ind Ltd Measuring method of substrate concentration or enzyme activity
CA1163908A (fr) * 1980-10-01 1984-03-20 Shyun-Long Yun Methode pour eliminer la turbidite dans un liquide biologique et reactif a cet effet
JPS5861000A (ja) * 1981-10-08 1983-04-11 Nippon Shoji Kk 体液成分の酵素的定量におけるビリルピンの干渉除去方法
JPS5876100A (ja) * 1981-10-30 1983-05-09 Ono Pharmaceut Co Ltd ラツカ−ゼの使用法
NZ199380A (en) * 1981-12-23 1986-08-08 J R Baker Determination of serum glucose levels in blood samples
JPS5918000A (ja) * 1982-07-23 1984-01-30 Amano Pharmaceut Co Ltd 生体成分の測定法及びそれに用いる試薬組成物
US4455371A (en) * 1982-03-03 1984-06-19 The Ohio State University Research Foundation Oxalate oxidase composition for assay of oxalate
JPS6036755B2 (ja) * 1982-08-20 1985-08-22 株式会社ヤトロン 生体液中の成分の測定方法
JPH0229318B2 (ja) * 1982-10-22 1990-06-28 Amano Pharma Co Ltd Seitaitaiekiseibunnosokuteiho
JPS59198971A (ja) * 1983-04-28 1984-11-10 Kyowa Hakko Kogyo Co Ltd ビリルビンオキシダ−ゼの製造法
US4610963A (en) * 1983-12-23 1986-09-09 Takara Suzo Co., Ltd. Novel glutathione oxidase, its production and use
JPS60224063A (ja) * 1984-04-20 1985-11-08 Terumo Corp 試験用具
US5002893A (en) * 1985-09-19 1991-03-26 Isolab, Inc. Single color reading method for determining fructosamine
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
US4956301A (en) * 1989-11-02 1990-09-11 Miles Inc. Test device and method of assaying for fructosamines

Also Published As

Publication number Publication date
DK314987A (da) 1987-12-22
AU583737B2 (en) 1989-05-04
US5288606A (en) 1994-02-22
YU46053B (sh) 1992-12-21
AU7452687A (en) 1987-12-24
KR880000797A (ko) 1988-03-29
EP0250991A3 (en) 1988-11-17
ES2053468T3 (es) 1994-08-01
JPS6315168A (ja) 1988-01-22
CA1298179C (fr) 1992-03-31
DE3620817A1 (de) 1987-12-23
JPH0640836B2 (ja) 1994-06-01
DK314987D0 (da) 1987-06-19
US5156947A (en) 1992-10-20
DE3783810D1 (de) 1993-03-11
EP0250991A2 (fr) 1988-01-07
ATE85131T1 (de) 1993-02-15
YU114287A (en) 1988-10-31

Similar Documents

Publication Publication Date Title
EP0250991B1 (fr) Procédé pour déterminer la teneur en fructoseamine de sérum et mélange de réactifs approprié
EP0037056B1 (fr) Procédé et agents diagnostiques pour la détection des réactions d'oxido-réduction
DE60028776T2 (de) Verfahren zum vorbehandeln von proben und zum quantifizieren von cholesterin in spezifischen lipoproteinen
DE1598756A1 (de) Mittel zur Bestimmung von Harnstoff in Fluessigkeiten
DE2850603A1 (de) Haemolysierloesung und verfahren zur haemolyse von blut
EP0077515B1 (fr) Procédé et réactif pour la détermination de l'hémoglobine glycosylée
DE2653537C3 (de) Verfahren und Mittel zur Bestimmung von Hydroperoxiden
EP0291060B1 (fr) Procédé pour la détermination de la fructosamine
EP0309882A2 (fr) Procédé pour la détermination spécifique de la teneur de fructoseamine dans le sérum ainsi que mélange réactionnel approprié
DE69026611T2 (de) Verfahren zur Bestimmung von Fruktosaminen
EP0185335B1 (fr) Procédé pour la détermination d'une allergie et pour la détermination spécifique d'allergène responsable de l'allergie
DE60033420T2 (de) Verfahren zur Quantifizierung von oxidiertem Glutathion
DE19713088C1 (de) Verfahren und Blutabnahmegefäß zur Aufbereitung von Blutproben für die Homocystein- und/oder Folatbestimmung
DE3125667C2 (de) Verfahren und Mittel zum Nachweis von Wasserstoffperoxid
DE2751904C2 (de) Verfahren und Mittel zur Bestimmung von Kreatinin in biologischen Flüssigkeiten
DE2500689C2 (fr)
DE69430410T2 (de) Methode zum Nachweis von Fructosamin
EP0105443A2 (fr) Méthode pour la production sélective d'espèce d'oxygène réduit et réactifs appropriés pour l'utilisation dans cette méthode
DE69817449T2 (de) Verfahren und Reagenz zur Bestimmung von direktem Bilirubin
DE2736517C2 (de) Triazinverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Eisenbestimmung
EP0351790B1 (fr) Méthode pour la détermination de fructosamine
EP0294714B1 (fr) Utilisation de polyvinylpyrrolidone (PVP) pour diminuer le trouble des sérums, des sérums contenant du PVP et procédé pour leur préparation
DE69615991T2 (de) Verfahren und Reagenz zum Nachweis von Ionen unter Verwendung von Maltose Derivaten
DE69620874T2 (de) Verfahren zur bestimmung von mit schwefelsäure konjugierter gallensäure und testsatz dafür
DE2818327A1 (de) Verfahren zur quantitativen bestimmung des gesamten gallensaeuregehalts einer analysenprobe

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870616

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19900816

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930127

Ref country code: NL

Effective date: 19930127

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19930127

Ref country code: GB

Effective date: 19930127

REF Corresponds to:

Ref document number: 85131

Country of ref document: AT

Date of ref document: 19930215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3783810

Country of ref document: DE

Date of ref document: 19930311

ET Fr: translation filed
ITF It: translation for a ep patent filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19930612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930630

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
GBV Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed]

Effective date: 19930127

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2053468

Country of ref document: ES

Kind code of ref document: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20000612

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20000613

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20000614

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20000623

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20000814

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010630

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010630

BERE Be: lapsed

Owner name: BOEHRINGER MANNHEIM G.M.B.H.

Effective date: 20010630

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020403

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050612